Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is a systemic immune-mediated disease associated with an increased risk of
comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome …

Background Guselkumab, tildrakizumab, and risankizumab, acting on interleukin (IL) 23
axis, have been recently approved for psoriasis management. However, real-life data …

Recent knowledge on the key role of interleukin (IL) 23/17 axis in psoriasis pathogenesis,
led to development of new biologic drugs. Risankizumab is a humanized immunoglobulin …

Psoriatic disease is a chronic, systemic immune‐mediated inflammatory disorder comprising
three major domains, skin, vascular and bone/joint inflammation. It is known for a long time …

Although innovative targeted therapies have positively revolutionized psoriasis treatment
shifting treatment goals to complete or almost complete skin clearance, primary or …

This is because bio-naïve patients are candidates for biological treatment with a higher PASI
than bio-experienced patients who have taken risankizumab following initial secondary …

Introduction Psoriasis is a chronic inflammatory disease of the skin. A few studies have
shown that psoriasis is an immune-mediated disease in which multiple immune cells play …

Introduction The advent of biological disease‐modifying anti‐rheumatic drugs (bDMARDs)
and, more recently, of Janus kinase inhibitors (JAKi) has had a major impact on the long …

Psoriasis and psoriatic arthritis are associated with an increased risk of mental health
conditions such as depression and anxiety. People with psoriatic disease (PsD) are also …